ISCT Asia 2026 poster

Rapid autologous CAR-T is increasingly important as CAR-T therapies for real world applications are desired to have rapid availability, preserved functional fitness, sustained target engagement, strong in-vivo proliferation, and durability. 

In this study, we evaluated Synecta T1 cell-derived nanoparticles (CDNPs), a physiological T-cell activation platform, combined with MARS GoFast , a streamlined 3-Step CAR-T manufacturing workflow, in production of CAR-T cells within an ultra-rapid <48 hour time frame. Then, we compared MARS GoFast CAR-T using a <72 hour manufacturing process based on CD3/CD28 bead-based technology (CD3/CD28 comparator).

Using Celldom’s cloneXplorer platform, individual CAR-T cells were tracked for target-cell killing, IFN-γ secretion, and clonal expansion. “Hero” CAR-T cells were operationally defined as CAR-positive T cells that cleared ≥2 NALM6 target cells and expanded to ≥8 total T cells from a single starting effector within 95 hours. The frequency and distribution of these functional phenotypes were then compared across manufacturing workflows.